*Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Office of New Drugs/ Office of Oncologic Diseases (OOD) Center for Drug Evaluation and Research (CDER), in collaboration with the Oncology Center of Excellence (OCE) at the Food and Drug Administration (FDA) in Silver Spring, Maryland.
The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs.
The 21st Century Cures Act is designed to accelerate medical product development and bring new innovations and advances faster and more efficiently to the patients who need them. Under this Act, FDA must evaluate the use of real-world evidence (RWE), generated from real-world Data (RWD) to modernize Trial Design and Evidence Development. Within the Oncology Center of Excellence (OCE), the newly established RWE Program has active opportunities to advance the use of RWD in OCE Scientific Priority Areas through collaborations with ongoing projects in Health Equity (specifically in understanding underrepresented groups), Special Populations (pediatric, older adults, rare cancers), Immunotherapy, Patient-Focused Drug Development, and Precision Oncology.
Under the guidance of a mentor the participant will gain knowledge in scientific project management, research collaborations, methodologic approaches, patient focused drug development, genomics, regulatory science, clinical trials and pharmacoepidemiology research, and RWE use for regulatory decision making.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.